An update from Kintara Therapeutics (KTRA) is now available.
Kintara Therapeutics has informed certain stockholders about an upcoming Special Meeting through a letter, with the details disclosed in a Current Report on Form 8-K. This report informs the SEC and is not considered an official filing under securities law, nor does it constitute a formal offer of securities. It pertains to a proposed merger with TuHURA Biosciences, for which Kintara has issued important documents including a Registration Statement and a definitive proxy statement/prospectus. Stockholders are encouraged to review these materials, available on the SEC’s website and Kintara’s investor relations page, to understand the implications of the merger before casting their votes. The document also contains forward-looking statements based on current expectations, which are subject to various risks and uncertainties that could cause actual results to differ.
See more data about KTRA stock on TipRanks’ Stock Analysis page.
